957230-68-1

Basic information

• Product Name: 3,6-dibroMopyrazine-2-carboxylic acid
• Synonyms: 3,6-dibromo-2-Pyrazinecarboxylic acid;2-Pyrazinamine, 5-bromo-3-(bromomethyl)-,hydrobromide (1:1);3,6-dibroMopyrazine-2-carboxylic acid
• CAS NO: 957230-68-1
• Molecular Formula: C5H2Br2N2O2
• Molecular Weight: 281.88958
• Mol File: 957230-68-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 368.724°C at 760 mmHg
• Flash Point: 176.798°C
• Appearance: /
• Density: 2.334g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3,6-dibroMopyrazine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-dibroMopyrazine-2-carboxylic acid(957230-68-1)
• EPA Substance Registry System: 3,6-dibroMopyrazine-2-carboxylic acid(957230-68-1)

Safety Data

• Hazardous Substances Data: 957230-68-1(Hazardous Substances Data)

Usage

General Description

3,6-Dibromopyrazine-2-carboxylic acid is a chemical compound with the molecular formula C6H3Br2N2O2. It is a derivative of pyrazine and contains two bromine atoms and one carboxylic acid group. 3,6-Dibromopyrazine-2-carboxylic acid is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It can also be used as a building block in organic synthesis for the preparation of various functionalized compounds. Additionally, 3,6-Dibromopyrazine-2-carboxylic acid has been studied for its potential biological and pharmacological properties, including its antimicrobial and anticancer activities.

InChI:InChI=1/C5H2Br2N2O2/c6-2-1-8-4(7)3(9-2)5(10)11/h1H,(H,10,11)

Upstream product

• 13301-04-7 3,6-dibromopyrazine-2-carboxylic acid methyl ester 
• 6966-01-4 methyl 3-amino-6-bromopyrazine-2-carboxylate 
• 16298-03-6 Methyl 3-amino-2-pyrazinecarboxylate 
• 5424-01-1 3-aminopyrazinoic acid 

Downstream Products

• 957230-70-5 3,6-dibromopyrazin-2-amine 

Relevant articles and documents

Discovery of a series of imidazopyrazine small molecule inhibitors of the kinase MAPKAPK5, that show activity using in vitro and in vivo models of rheumatoid arthritis

MAPKAPK5 has been proposed to play a role in regulation of matrix metalloprotease expression and so to be a potential target for intervention in rheumatoid arthritis. We present here the identification of a series of compounds against this target which are effective in both biochemical and cell assays. The expansion of the series is described, along with early SAR and pharmacokinetics for some representative compounds.

FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel salts of a [1.2.4]triazolo[1,5-a]pyrazine compound according to Formula I: The salts may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, and others.

IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula ( I ) represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.